Helix Biopharma Corp Stock Analysis
| HBP Stock | CAD 0.84 0.02 2.44% |
Helix BioPharma Corp is overvalued with Real Value of 0.75 and Hype Value of 0.84. The main objective of Helix BioPharma stock analysis is to determine its intrinsic value, which is an estimate of what Helix BioPharma Corp is worth, separate from its market price. There are two main types of Helix BioPharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Helix BioPharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Helix BioPharma's stock to identify patterns and trends that may indicate its future price movements.
The Helix BioPharma stock is traded in Canada on Toronto Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Canada. Helix BioPharma is usually not traded on Canada Day, Civic Holiday, Labour Day, Thanksgiving Day, Christmas Day, Boxing Day, New Year 's Day, Family Day, Good Friday, Victoria Day. Helix Stock trading window is adjusted to America/Toronto timezone.
Helix |
Helix Stock Analysis Notes
The company recorded a loss per share of 1.05. Helix BioPharma Corp had not issued any dividends in recent years. The entity had 1:5 split on the 16th of August 2024. Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. Helix BioPharma Corp. is headquartered in Richmond Hill, Canada. HELIX BIOPHARM operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 22 people. To learn more about Helix BioPharma Corp call Jacek Antas at 905-841-2300 or check out https://www.helixbiopharma.com.Helix BioPharma Corp Investment Alerts
| Helix BioPharma Corp generated a negative expected return over the last 90 days | |
| Helix BioPharma Corp has high historical volatility and very poor performance | |
| Helix BioPharma Corp has some characteristics of a very speculative penny stock | |
| Helix BioPharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Helix BioPharma Corp has accumulated 1.58 M in total debt. Helix BioPharma Corp has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Helix BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Helix BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Helix BioPharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Helix to invest in growth at high rates of return. When we think about Helix BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Helix BioPharma Corp has accumulated about 938 K in cash with (5.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Latest headline from news.google.com: Helix BioPharma Corp. Announces Resignation of Praveen Varshney as Chief Financial Officer - Marketscreener.com |
Helix Largest EPS Surprises
Earnings surprises can significantly impact Helix BioPharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2009-10-29 | 2009-07-31 | -0.08 | -0.06 | 0.02 | 25 |
Helix Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Helix BioPharma's market, we take the total number of its shares issued and multiply it by Helix BioPharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Helix Profitablity
Helix BioPharma's profitability indicators refer to fundamental financial ratios that showcase Helix BioPharma's ability to generate income relative to its revenue or operating costs. If, let's say, Helix BioPharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Helix BioPharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Helix BioPharma's profitability requires more research than a typical breakdown of Helix BioPharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (6.22) | (5.91) | |
| Return On Capital Employed | 104.12 | 109.33 | |
| Return On Assets | (6.22) | (5.91) | |
| Return On Equity | 102.93 | 108.08 |
Management Efficiency
Helix BioPharma Corp has return on total asset (ROA) of (4.5865) % which means that it has lost $4.5865 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (22.2062) %, meaning that it generated substantial loss on money invested by shareholders. Helix BioPharma's management efficiency ratios could be used to measure how well Helix BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Helix BioPharma's Return On Capital Employed is very stable compared to the past year. As of the 27th of November 2024, Return On Equity is likely to grow to 108.08, though Return On Tangible Assets are likely to grow to (5.91). At this time, Helix BioPharma's Debt To Assets are very stable compared to the past year. As of the 27th of November 2024, Asset Turnover is likely to grow to 0.53, while Total Assets are likely to drop about 1.4 M.| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (5.34) | (5.61) | |
| Price Book Value Ratio | (568.43) | (596.85) | |
| Enterprise Value Multiple | (5.34) | (5.61) | |
| Price Fair Value | (568.43) | (596.85) | |
| Enterprise Value | 50.1 M | 91.4 M |
Leadership effectiveness at Helix BioPharma Corp is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta (0.84) | Return On Assets (4.59) | Return On Equity (22.21) |
Technical Drivers
As of the 27th of November, Helix BioPharma retains the Standard Deviation of 8.06, market risk adjusted performance of 0.1511, and Risk Adjusted Performance of (0.01). Helix BioPharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Helix BioPharma Corp Price Movement Analysis
The output start index for this execution was three with a total number of output elements of fifty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Helix BioPharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Helix BioPharma Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Helix BioPharma Outstanding Bonds
Helix BioPharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Helix BioPharma Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Helix bonds can be classified according to their maturity, which is the date when Helix BioPharma Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Helix BioPharma Predictive Daily Indicators
Helix BioPharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Helix BioPharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 0.84 | |||
| Day Typical Price | 0.84 | |||
| Price Action Indicator | 0.01 | |||
| Period Momentum Indicator | 0.02 | |||
| Relative Strength Index | 21.39 |
Helix BioPharma Forecast Models
Helix BioPharma's time-series forecasting models are one of many Helix BioPharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Helix BioPharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Helix Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Helix BioPharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Helix shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Helix BioPharma. By using and applying Helix Stock analysis, traders can create a robust methodology for identifying Helix entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (4.70) | (4.94) | |
| Operating Profit Margin | (2.86) | (3.00) | |
| Net Loss | (4.71) | (4.94) | |
| Gross Profit Margin | 0.68 | 0.69 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Helix BioPharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.